Published by Josh White on 4th July 2024
(Sharecast News) - Hutchmed China announced on Thursday that the China National Medical Products Administration (NMPA) has accepted its new drug application (NDA) for tazemetostat, granting it priority review for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL).